Healthy
Conditions
Brief summary
This study aims to evaluate the influence of tegoprazan or RAPA113 on the pharmacodynamics/Pharmacokinetics of following co-administration of tegoprazan or RAPA113 and clopidogrel in healthy male volunteers.
Detailed description
Evaluation Criteria: * Primary outcome Pharmacodynamic assessments using P2Y12 assay * Secondary outcome Pharmacokinetics assessments on Cmax,ss, AUCτ,ss, tmax,ss, Cmin,ss , CLss/F of Clopidogrel * Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory test
Interventions
DRUGClopidogrel 75mg
Clopidogrel 75 mg tablet
DRUGTegoprazan 50 mg
Tegoprazan 50 mg tablet
DRUGRAPA113
RAPA113 tablet
Sponsors
HK inno.N Corporation
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult males aged ≥ 19 years and ≤ 50 years on the date of the written informed consent * Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 18.5 kg/m2 and ≤ 27.0 kg/m2 at the time of screening * Helicobacter pylori negative * Voluntarily decided to participate in the study and provided written informed consent before any screening procedure
Exclusion criteria
* Has a history of or currently has clinically significant liver, kidney, nervous system, immune system, respiratory system, endocrine system, blood, tumor, cardiovascular system or psychiatric disease * Has a history of gastrointestinal diseases (such as Crohn's disease, ulcer, etc.) or surgery (except for simple appendectomy or hernia) that can affect the absorption of drugs * Has a genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption * Has a clinically significant history of hemorrhage (e.g. Gastric ulcers, intracranial bleeding, haemophilia, gastrointestinal bleeding, urinary tract bleeding, vitreous hemorrhage, etc.) * P2Y12 Reaction Unit (PRU) by P2Y12 assay outside the upper/lower limit of normal range by 10% at screening * Considered ineligible to participate in the study based on screening test(by asking condition, vital sign, 12-lead ECG, physical exam, laboratory test etc.) results : 1. Platelet, PT and aPTT levels outside the upper/lower limit of normal range by 10% 2. AST (GOT), and ALT (GPT) levels greater than 1.25x of the upper limit of normal range 3. Blood total bilirubin levels greater than 1.5x of the upper limit of normal range 4. Hemoglobin levels less than 12.0 g/dL 5. eGFR (estimated Glomerular Filtration Rate) using MDRD (Modification of Diet in Renal Disaster) \< 60 mL/min/1.73 m2 : eGFR (estimated glomerular filtration rate) (mL/min/1.73m2) = 175 x \[serum creatinine (mg/dL)\]-1.154 x \[age\]-0.203 6. positive as a result of serum examination (B-type hepatitis test, hepatitis C test, human immunodeficiency virus test, syphilis test) 7. Systolic blood pressure \< 90 mmHg or \> 150 mmHg, diastolic blood pressure \< 50 mmHg or \> 100 mmHg, or pulse rate \< 45 beats/minute or \> 100 beats/minute when vital signs are measured in sitting position after resting for at least 5 minutes during screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in P2Y12 Reaction Unit (PRU) from baseline | Pre-dose(0h) on days 1, 3, 5, 7 and 8 in each period | Pharmacodynamics blood sampling to measure PRU using VerifyNow® system |
Countries
South Korea
Outcome results
None listed